Baxter International Poised to Lead Global Protein Therapeutics Market Through 2028
January 12, 2023
Trending News ☀️
Baxter International ($NYSE:BAX) is a leading global medical products company focused on providing innovative healthcare solutions. It has a strong presence in the biopharmaceuticals, medical device, and generic pharmaceuticals markets, and has developed a platform for the development of protein therapeutics. The company has been investing heavily in research and development to create products that meet the needs of healthcare professionals and patients. This growth is primarily driven by increasing demand for biopharmaceuticals, rising prevalence of chronic diseases, and advances in biotechnology.
In addition, the growing demand for personalized medicine and adoption of advanced technologies such as gene therapy are expected to drive market growth. Abbott Laboratories and Baxter International are among the leading players in the market. Both companies have invested heavily in developing new products and technologies, as well as expanding their product portfolios. Abbott Laboratories is focused on developing biologics, while Baxter International has developed a platform for the development of protein therapeutics. By 2028, Baxter International is poised to lead the global protein therapeutics market, owing to its strong research and development capabilities, focus on innovation, and strong product portfolio. The company has developed an extensive portfolio of products for various therapeutic areas such as oncology, diabetes, cardiovascular disease, and neurological disorders. Furthermore, its strategic partnerships with leading providers of biopharmaceuticals and medical devices have enabled it to further enhance its product offerings. Its commitment to innovation, extensive product portfolio, and strategic partnerships will enable it to capitalize on the growing demand for protein therapeutics in the coming years.
Market Price
The medical device and healthcare products manufacturer opened at $45.9 and closed at $45.4 on Wednesday, down by 0.7% from its prior closing price of 45.7. This downward trend is expected to be reversed in the coming years as Baxter International is poised to make a major impact in the global protein therapeutics market. The company’s advancements in biotechnology and its expertise in developing innovative treatments and therapies have enabled it to become a leader in the industry. It has a strong portfolio of products and services, including biopharmaceuticals, vaccines, antibodies, and recombinant proteins, which are being used to treat many different diseases. Moreover, they have recently launched their next-generation protein therapeutics platform, Procyte, which is designed to accelerate the development and commercialization of novel protein therapeutics. The company is investing heavily in research and development for new treatments and therapies for various diseases, including cancer and diabetes.
In addition, it has acquired multiple companies that specialize in protein therapeutics, allowing it to access new technologies and expand its product portfolio. Overall, Baxter International is well-positioned to take advantage of the growing demand for protein therapeutics in the coming years. The company’s strong product pipeline and investments in R&D will ensure that it remains at the forefront of the industry. With its focus on innovation and expansion into new markets, Baxter International is positioned to be a major player in the global protein therapeutics market through 2028. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Baxter International. More…
| Total Revenues | Net Income | Net Margin |
| 14.74k | -2.38k | -4.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Baxter International. More…
| Operations | Investing | Financing |
| 1.47k | -10.94k | 7.96k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Baxter International. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 27.96k | 22.39k | 10.98 |
Key Ratios Snapshot
Some of the financial key ratios for Baxter International are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.6% | -18.1% | -13.1% |
| FCF Margin | ROE | ROA |
| 5.1% | -16.7% | -4.3% |
VI Analysis
Baxter International is an American healthcare company that provides medical products and services worldwide. It is important to evaluate the fundamentals of a company before investing in it, and VI App makes this process easier. According to the VI Risk Rating, investing in Baxter International is a high-risk endeavor due to several factors. Our app has detected four risk warnings in the balance sheet, cash flow statement, non-financial and financial journals. The balance sheet can provide a snapshot of a company’s financial health by showing its assets, liabilities, and shareholder equity. The cash flow statement shows the flow of cash into and out of a company. Non-financial journals provide information about the company’s operations, such as revenues and costs. Finally, financial journals reflect the company’s performance in terms of profitability, liquidity, and leverage. From these assessments, it is clear that Baxter International is a high-risk investment, so investors should proceed with caution. To understand the full risk profile of Baxter International, investors should register with VI App to access our detailed analysis. With access to our data, investors can make informed decisions about their investments and minimize their risk exposure. More…
VI Peers
Baxter International Inc is a large medical device company. Its main competitors are Utah Medical Products Inc, Clarity Medical Group Holding Ltd, and Merit Medical Systems Inc.
– Utah Medical Products Inc ($NASDAQ:UTMD)
The company’s market cap is $313.74 million and its ROE is 11.43%. Utah Medical Products, Inc. engages in the design, manufacture, and marketing of medical devices. It operates through the following segments: Pregnancy & Newborn, Patient Care, and Animal Health. The Pregnancy & Newborn segment offers a line of products used by obstetricians, gynecologists, and neonatal caregivers for the health and well-being of pregnant women and their babies. The Patient Care segment provides a line of products used by hospitals, clinics, and home healthcare providers for the treatment of respiratory and other conditions. The Animal Health segment offers a line of products used by veterinarians for the health and well-being of animals.
– Clarity Medical Group Holding Ltd ($SEHK:01406)
According to Clarity Medical Group Holding Ltd’s market cap as of 2022, the company is worth 599.47 million. Clarity Medical Group Holding Ltd is a Medical Group that provides healthcare services. The company was founded in 2014 and is headquartered in Hong Kong.
– Merit Medical Systems Inc ($NASDAQ:MMSI)
Medstronic is a medical device company that manufactures and sells a variety of medical devices and equipment. The company has a market cap of 3.29B as of 2022 and a ROE of 5.86%. Medtronic’s products are used in a variety of medical procedures, including cardiac surgery, vascular surgery, and neurology.
Summary
Baxter International Inc. is well-positioned to become a leader in the global protein therapeutics market through 2028. With strong product offerings and a focus on innovation, Baxter is expected to experience significant growth in the coming years. The company has an impressive track record of success and is investing heavily in expanding its pipeline of products. Baxter is also focused on providing tailored customer solutions and delivering value-based healthcare solutions to its customers.
The company is expected to benefit from increased demand for biopharmaceuticals and specialized treatments. Overall, Baxter International is well-positioned to capitalize on industry trends and remain competitive in the global protein therapeutics market.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
